Once daily treatment with Denali's oral candidate DNL343 failed to reduce NfL levels in adults with ALS in the HEALEY trial.
Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...
Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...
MedPage Today on MSN2d
Alzheimer's Research Funds in Limbo; X Chromosome and the Brain; Stress and StrokeTris Pharma announced positive topline results from the ALLEVIATE-2 phase III clinical trial of investigational cebranopadol to treat moderate-to-severe acute pain after bunionectomy surgery. Axonal ...
Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug.
On March 5, 2025, Denali Therapeutics ( DNLI) Inc. provided an update that further analyses from Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Denali Therapeutics said additional analyses of investigational DNL343 did not demonstrate a treatment effect on ...
Denali Therapeutics Inc.’s DNLI share price has dipped by 10.43%, which has investors questioning if this is right time to buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback